We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
N-glycosylation of serum proteins for the assessment of patients with IgD multiple myeloma.
- Authors
Jie Chen; Meng Fang; Xiaoling Chen; Changhong Yi; Jun Ji; Cheng Cheng; Mengmeng Wang; Xing Gu; Quansheng Sun; Chunfang Gao; Chen, Jie; Fang, Meng; Chen, Xiaoling; Yi, Changhong; Ji, Jun; Cheng, Cheng; Wang, Mengmeng; Gu, Xing; Sun, Quansheng; Gao, Chunfang
- Abstract
<bold>Background: </bold>Because glycosylation is one of the most common post-translational modifications of proteins and because changes in glycosylation have been shown to have a significant correlation with the development of many cancer types, we investigated the serum N-glycome used to diagnose, stage and evaluate the pathological outcomes in IgD multiple myeloma.<bold>Methods: </bold>Serum samples were available for 20 patients with IgD multiple myeloma, 41 patients with light chain multiple myeloma and 42 healthy control subjects. Serum N-glycans were released and analysed using DNA sequencer-assisted fluorophore-assisted capillary electrophoresis.<bold>Results: </bold>Characteristic changes were revealed in the serum N-glycome of IgD myeloma. In particular, three N-glycans (NG1(6)A2F, Peak3; NG1(3)A2F, Peak4; NA2FB, Peak7) showed increased clinical value. The best area under the ROC curve of NG1(6)A2F to diagnose IgD myeloma was 0.981, with a 95.0% sensitivity and 95.2% specificity, and that of NG1(3)A2F was 0.936, with a 95.0% sensitivity and 78.6% specificity. The best area under the ROC curve of NA2FB/NG1(3)A2F to differentially diagnose IgD myeloma versus light chain myeloma was 0.744, with a 95.3% sensitivity and 50.0% specificity. The level of NG1(3)A2F was correlated with the international staging system, while the higher abundance of NA2FB presented in IgD myeloma was predictive of a shorter progression-free survival.<bold>Conclusions: </bold>The advent of serum N-glycan signatures may play a role in the diagnosis, staging and prognosis of IgD myeloma and will serve as the foundation for a precision medicine approach to this rare subtype of multiple myeloma.
- Subjects
GLYCOSYLATION; MULTIPLE myeloma; NUCLEOTIDE sequence; PROGRESSION-free survival; INDIVIDUALIZED medicine
- Publication
BMC Cancer, 2017, Vol 17, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-017-3891-3